2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 10:55, 12 November 2023
, 12 November 2023no edit summary
(→Todo) |
No edit summary |
||
| Line 85: | Line 85: | ||
===Reduced NMN (NMNH)=== | ===Reduced NMN (NMNH)=== | ||
[[Reduced Nicotinamide Mononucleotide (NMNH)]] is a novel, potentially more effective [[NAD+ Precursor|NAD+ precursor]]. | [[Reduced Nicotinamide Mononucleotide (NMNH)]] is a novel, potentially more effective [[NAD+ Precursor|NAD+ precursor]]. | ||
== Bioavailability of NMN == | |||
Bioavailability is a crucial factor in the effectiveness of any dietary supplement, including Nicotinamide Mononucleotide (NMN). It refers to the proportion of a substance that enters the circulation when introduced into the body and is thus able to have an active effect. In the case of NMN, bioavailability determines how much of the compound reaches the bloodstream and subsequently contributes to NAD+ biosynthesis. | |||
One of the main challenges with NMN bioavailability is its absorption and transportation within the body. When taken orally, NMN needs to be absorbed through the gastrointestinal tract, which can present barriers to its effective uptake. | |||
* '''Molecular Size''': NMN's relatively large molecular size compared to other NAD+ precursors (like NR, or nicotinamide riboside) poses a challenge for its absorption in the gut. | |||
* '''Enzymatic Degradation''': NMN can be subject to degradation by enzymes in the digestive tract, potentially reducing the amount that actually enters the bloodstream. | |||
To address these challenges, various strategies and formulations have been developed: | |||
* '''Liposomal Encapsulation''': Liposomal NMN involves wrapping NMN molecules in a lipid layer, which can help protect them from degradation in the digestive system and enhance absorption. | |||
* '''Sublingual Administration''': Taking NMN sublingually (under the tongue) is proposed to increase its bioavailability by allowing direct absorption into the bloodstream, bypassing the digestive system. | |||
* '''Microcrystalline Formulation''': MIB-626, a microcrystalline form of NMN developed by MetroBiotech, is believed to offer enhanced stability and bioavailability. | |||
While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | |||
==Potential Benefits== | ==Potential Benefits== | ||